AGIO Stock Cash Flow Statements

Agios Pharmaceuticals Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Agios Pharmaceuticals Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30

operating activities
net income	-112,020,000	-89,289,000	-96,523,000	947,915,000	-96,118,000	-81,549,000	-95,940,000	-91,324,000	-83,806,000	-81,018,000	36,526,000	-81,747,000	-91,806,000	-94,774,000	-94,627,000	-88,766,000	-86,217,000	1,874,325,000	-97,657,000	-98,979,000	-90,478,000	-40,256,000	-102,350,000	-106,173,000	-109,871,000	-93,078,000	-91,794,000	-94,664,000	-68,745,000	-90,825,000	-88,285,000	-77,137,000	-83,082,000	-66,166,000	-56,486,000	-62,834,000	-55,953,000	-23,198,000	-40,622,000	-40,256,000	-31,897,000	-4,957,000	-26,664,000	3,704,000	-18,296,000	-12,248,000	-12,382,000	-11,177,000
adjustments to reconcile net income from operations to net cash from operating activities:
depreciation and amortization	1,259,000	1,278,000	1,367,000	1,345,000	1,593,000	1,348,000	1,403,000	1,623,000	1,807,000	1,790,000	1,814,000	1,981,000	2,291,000	2,478,000	2,202,000	2,209,000	2,350,000	2,479,000	2,677,000
stock-based compensation expense	14,692,000	11,359,000	10,903,000	11,145,000	11,565,000	9,234,000	13,814,000	9,076,000	11,737,000	10,139,000	11,465,000	11,156,000	11,165,000	15,510,000	11,621,000	12,148,000	14,885,000	14,854,000	16,595,000	18,407,000	20,430,000	19,690,000	17,130,000	18,588,000	18,547,000	18,108,000	18,187,000	24,193,000	16,455,000	14,522,000	12,681,000	12,207,000	12,187,000	10,734,000	9,840,000	12,143,000	10,996,000	9,107,000	9,353,000	9,373,000	8,177,000	5,060,000	4,728,000	2,892,000	2,381,000	1,505,000	1,165,000	1,112,000
net accretion of discount on marketable securities	-2,420,000	-1,348,000	-5,616,000	-3,734,000	-2,609,000	-2,527,000
gain on disposal of property and equipment					0	-39,000				-150,000
non-cash operating lease expense	3,076,000	3,018,000	2,962,000	2,909,000	2,856,000	2,803,000	2,753,000	2,704,000	2,655,000	2,608,000	2,563,000	2,513,000	2,483,000	2,436,000	2,408,000	2,369,000	2,343,000	2,417,000	2,291,000	2,256,000	2,232,000	2,203,000	2,191,000	2,133,000	2,123,000	2,085,000
expense associated with license agreement							0
realized gain on investments	0	-2,000	1,000	-15,000	-1,000	-152,000	0
changes in operating assets and liabilities:
accounts receivable	-1,642,000	765,000	-991,000	644,000	-309,000	-643,000	-1,634,000	1,075,000	-473,000	428,000	-388,000	-220,000	-1,058,000	-540,000					-2,339,000	-6,966,000	-210,000	-2,861,000	-1,846,000	41,000	-2,792,000	721,000	-2,445,000
inventory	-1,243,000	-1,989,000	-1,187,000	-2,492,000	-867,000	-3,994,000	-1,802,000	-1,603,000	-4,297,000	-2,882,000	-3,316,000	-1,116,000	-1,575,000	-2,485,000					-3,327,000	-140,000	-1,453,000	-2,447,000	-1,482,000	-1,190,000	-2,331,000	-1,459,000	-6,000
prepaid expenses and other current and non-current assets	-1,622,000	-2,124,000	-948,000	-5,349,000	4,577,000	-4,091,000	3,393,000	-1,663,000	2,451,000	-348,000	7,479,000	-4,099,000	-165,000	-3,391,000	-7,597,000	-10,795,000	-4,833,000	-3,621,000	5,434,000	-1,676,000	2,417,000	-6,774,000	-4,190,000	-1,035,000	-344,000	-2,173,000	-563,000	-702,000	512,000	1,901,000	-2,086,000	-2,027,000	1,008,000	-3,425,000	-231,000
accounts payable	3,905,000	-2,821,000	-756,000	7,089,000	-1,162,000	1,430,000	-3,532,000	1,636,000	2,959,000	-9,796,000	8,064,000	2,615,000	-2,236,000	-5,007,000	5,200,000	2,224,000	-2,620,000	-2,941,000	13,529,000	-116,000	-5,515,000	-2,009,000	1,067,000	4,523,000	3,065,000	-4,939,000	342,000	368,000	-1,729,000	-4,469,000	4,587,000	-4,188,000	5,924,000	-994,000	1,833,000	-2,087,000	4,048,000	-293,000	5,539,000	-114,000	1,455,000	-2,665,000	5,223,000	670,000	964,000	720,000	1,208,000	-907,000
accrued expenses and other current liabilities	14,528,000	-26,100,000		-3,435,000	11,613,000	-18,038,000		1,301,000	6,730,000	-7,891,000		1,373,000	8,636,000	-12,220,000		-120,000	10,150,000	-12,697,000
income taxes payable	-683,000	-188,000	-51,811,000																																												-3,684,000	116,000
operating lease liabilities	-4,180,000	-4,048,000	-3,846,000	-3,786,000	-3,727,000	-3,649,000	-3,502,000	-3,448,000	-3,392,000	-3,321,000	-3,182,000	-2,095,000	-3,146,000	-2,405,000	-2,212,000	-1,684,000	-2,127,000	-1,504,000	-2,015,000	-1,963,000	-1,920,000	-2,229,000	-2,671,000	-541,000	-1,520,000	-2,129,000
other non-current liabilities								0	-157,000	-1,966,000		0
net cash from operating activities	-77,124,000	-111,489,000	-133,167,000	-84,218,000	-72,589,000	-99,867,000	-72,488,000	-61,643,000	-66,748,000	-95,183,000	-66,163,000	-71,351,000	-74,229,000	-97,735,000	9,141,000	-85,184,000	-117,294,000	-120,749,000	-49,397,000	-68,207,000	-67,797,000	-105,358,000	-93,611,000	-85,589,000	-88,151,000	-103,271,000	-74,187,000	-63,839,000	-67,395,000	-99,000,000	-74,454,000	-77,715,000	-58,989,000	-74,074,000	-51,223,000	-49,030,000	157,824,000	-19,009,000	-30,529,000	-24,815,000	3,980,000	-25,585,000	-7,775,000	-23,467,000	-1,071,000	-27,040,000	-13,617,000	-14,980,000
capex	-875,000	-545,000	-967,000	-419,000	-158,000	-141,000	-193,000	-361,000	3,000	-399,000	-113,000	-38,000	-1,926,000	-2,804,000	-3,310,000	452,000	-199,000	-1,006,000	-737,000	-8,640,000	-6,056,000	989,000	-3,745,000	-484,000	-1,463,000	-1,311,000	-448,000	-4,004,000	-601,000	-827,000	-495,000	-3,176,000	135,000	-80,000	-1,222,000	-4,289,000	-1,981,000	-1,926,000	-2,186,000	-3,750,000	-10,882,000	2,805,000	-1,489,000	-443,000	-87,000	0	-219,000	-99,000
free cash flows	-77,999,000	-112,034,000	-134,134,000	-84,637,000	-72,747,000	-100,008,000	-72,681,000	-62,004,000	-66,745,000	-95,582,000	-66,276,000	-71,389,000	-76,155,000	-100,539,000	5,831,000	-84,732,000	-117,493,000	-121,755,000	-50,134,000	-76,847,000	-73,853,000	-104,369,000	-97,356,000	-86,073,000	-89,614,000	-104,582,000	-74,635,000	-67,843,000	-67,996,000	-99,827,000	-74,949,000	-80,891,000	-58,854,000	-74,154,000	-52,445,000	-53,319,000	155,843,000	-20,935,000	-32,715,000	-28,565,000	-6,902,000	-22,780,000	-9,264,000	-23,910,000	-1,158,000	-27,040,000	-13,836,000	-15,079,000
investing activities
purchases of marketable securities	-130,797,000	-174,903,000	-198,326,000	-995,503,000	-104,545,000	-244,059,000	-90,440,000	-95,004,000	-104,135,000	-128,351,000	-248,563,000	-174,471,000	-251,831,000	-355,916,000	-426,810,000	-452,515,000	-437,033,000	-61,863,000	-126,406,000	-241,023,000	-134,690,000	-54,911,000	-293,744,000	-50,591,000	-66,810,000	-77,421,000	-177,952,000	-162,704,000	-261,693,000	-330,971,000	-84,177,000	-135,969,000	-441,816,000	-26,740,000	-138,480,000	-141,298,000	-15,126,000	-211,163,000	-134,520,000	-112,452,000	-70,679,000	-35,526,000	-621,836,000	-89,045,000	-91,526,000	-34,812,000	-26,551,000	-96,303,000
proceeds from maturities and sales of marketable securities	220,638,000	288,256,000	150,135,000	157,579,000	141,947,000	368,722,000	186,187,000	151,039,000	151,257,000	186,196,000	198,879,000	278,579,000	336,570,000	332,147,000	336,893,000	219,762,000	139,133,000	134,016,000	198,819,000	119,983,000	161,382,000	167,501,000	115,795,000	133,010,000	132,561,000	210,811,000	166,200,000	168,615,000	166,795,000	164,871,000	127,305,000	204,405,000	167,126,000	136,585,000	62,184,000	81,980,000	53,600,000	198,868,000	157,664,000	145,908,000	113,767,000	84,311,000	336,023,000	74,004,000	72,941,000	22,560,000	6,360,000	15,680,000
payments associated with license agreement							0
purchases of property and equipment	-875,000	-766,000	-967,000	-419,000	-158,000	-141,000	-234,000	-369,000	3,000	-399,000	-113,000	-38,000	-1,926,000	-2,804,000	-4,502,000	22,000	-249,000	-1,012,000	-1,017,000	-5,204,000	-4,233,000	-4,455,000	-6,824,000	-2,038,000	-1,271,000	-2,038,000	-1,053,000	-3,140,000	-1,361,000	-1,432,000	-1,280,000	-2,019,000	-1,035,000	-293,000	-1,222,000	-3,426,000	-2,734,000	-2,533,000	-2,186,000	-3,299,000	-10,882,000	-3,797,000	-1,489,000	-628,000	-86,000	-13,000	-219,000	-99,000
proceeds from sale of equipment			0	0	0	40,000	0	1,175,000	0	150,000
net cash from investing activities	78,966,000	112,587,000	-49,158,000	250,793,000	37,244,000	124,562,000	95,513,000	39,341,000	47,125,000	57,596,000	82,951,000	104,070,000	82,813,000	-26,573,000	-1,897,355,000	-232,731,000	-298,149,000	1,874,077,000	71,396,000	-126,244,000	22,459,000	108,135,000	-184,773,000	80,381,000	64,480,000	131,352,000	-12,805,000	2,771,000	-96,259,000	-167,532,000	41,848,000	66,417,000	-275,725,000	109,552,000	-77,518,000	-62,744,000	35,740,000	-14,828,000	20,958,000	30,157,000	32,206,000	44,988,000	-287,302,000	-15,098,000	-18,671,000	-12,265,000	-20,410,000	-80,722,000
financing activities
net proceeds from stock option exercises and employee stock purchase plan	65,000	1,619,000	4,842,000	2,637,000	1,099,000	5,864,000	847,000	1,882,000	237,000	2,467,000	105,000	1,271,000	16,000	1,289,000	267,000	4,009,000	25,673,000	7,347,000	668,000	3,532,000	1,652,000	5,465,000	518,000	3,337,000	3,808,000	4,860,000	1,016,000	7,223,000	9,711,000	12,259,000		5,515,000	2,699,000	4,146,000		1,202,000	1,449,000	1,108,000		2,173,000	1,091,000	2,029,000
net cash from financing activities	65,000	1,619,000	4,842,000	2,637,000	1,099,000	5,864,000	847,000	1,882,000	237,000	2,467,000	22,000	1,187,000	-67,000	1,208,000	-18,586,000	-250,985,000	-503,458,000	7,261,000	582,000	3,448,000	252,103,000	5,385,000	277,606,000	3,337,000	3,808,000	4,860,000	1,016,000	7,223,000	9,508,000	528,277,000	2,589,000	5,322,000	273,153,000	4,046,000	3,993,000	163,228,000	1,449,000	1,108,000	1,287,000	2,173,000	1,091,000	1,822,000	239,059,000	367,000	95,152,000	582,000	-424,000	124,232,000
net change in cash and cash equivalents	1,907,000	2,717,000	-177,483,000	169,212,000	-34,246,000	30,559,000	23,872,000	-20,420,000	-19,386,000	-35,120,000	16,810,000	33,906,000	8,517,000	-123,100,000	-197,098,000	-568,900,000	-918,901,000	1,760,589,000	22,581,000	-191,003,000	206,765,000	8,162,000	-778,000	-1,871,000	-19,863,000	32,941,000	-85,976,000	-53,845,000	-154,146,000	261,745,000	-30,017,000	-5,976,000	-61,561,000	39,524,000
cash and cash equivalents at beginning of the period	0	76,247,000	0	0	0	88,205,000	0	0	0	139,259,000	0	0	0	203,126,000	0	0	0	127,436,000	0	0	0	80,931,000	0	0	0	70,502,000	0	0	0	102,724,000	0	0	0	160,754,000	0	0	0	71,764,000	0	0	0	14,031,000	0	0	0	71,560,000	0	0
cash and cash equivalents at end of the period	1,907,000	78,964,000	-177,483,000	169,212,000	-34,246,000	118,764,000	23,872,000	-20,420,000	-19,386,000	104,139,000	16,810,000	33,906,000	8,517,000	80,026,000	-197,098,000	-568,900,000	-918,901,000	1,888,025,000	22,581,000	-191,003,000	206,765,000	89,093,000	-778,000	-1,871,000	-19,863,000	103,443,000	-85,976,000	-53,845,000	-154,146,000	364,469,000	-30,017,000	-5,976,000	-61,561,000	200,278,000	-124,748,000	51,454,000	195,013,000	39,035,000	-8,284,000	7,515,000	37,277,000	35,256,000	-56,018,000	-38,198,000	75,410,000	32,837,000	-34,451,000	28,530,000
supplemental disclosure of non-cash investing and financing transactions
additions to property and equipment in accounts payable
net cash taxes paid							-17,000
additions to property and equipment in accounts payable and accrued expenses		221,000					41,000	8,000							1,192,000	430,000	50,000	6,000	280,000	-3,436,000	-1,823,000	5,444,000	3,079,000	1,554,000	-192,000	727,000	605,000	-864,000	760,000	605,000	785,000	-1,157,000	1,170,000	213,000						-451,000
net cash taxes (returned) paid		188,000			-78,000	-525,000
adjustments to reconcile net income to net cash from operating activities:
gain on sale of contingent payments			0
milestone payment from gain on sale of oncology business			0
other receivables											-157,000	-1,070,000	2,661,000	-987,000	2,612,000	1,141,000																							-381,000	2,289,000	1,625,000	-4,573,000
accrued expenses																			10,598,000	8,757,000	6,372,000	-14,967,000	2,631,000	-2,469,000	12,168,000	-5,097,000	17,160,000	-696,000	9,303,000	-17,144,000	2,764,000	1,150,000
other liabilities
proceeds from sale of contingent payments			0
proceeds from milestone payment from gain on sale of oncology business			0
payments on financing lease obligations											-83,000	-84,000	-83,000	-81,000	195,000	-603,000	-84,000	-86,000	-86,000	-84,000	-86,000	-80,000
supplemental disclosure of non-cash investing and financing transactions:
(gain) loss on disposal of property and equipment
less: net income from discontinued operations															3,957,000	-4,507,000	-3,427,000	1,965,202,000
net income from continuing operations											36,526,000	-81,747,000	-91,806,000	-94,774,000	-98,584,000	-84,259,000	-82,790,000	-90,877,000
net (accretion of discount) amortization of premium on marketable securities							-393,000	1,080,000
net cash from operating activities - continuing operations												-71,351,000	-74,229,000	-97,735,000		-74,866,000	-69,003,000	-90,226,000
net cash from operating activities - discontinued operations															-4,102,000	-10,318,000	-48,291,000	-30,523,000
net cash from investing activities - continuing operations												104,070,000	82,813,000	-26,573,000		-232,731,000	-298,149,000	71,141,000
net cash from investing activities - discontinued operations															0	0	0	1,802,936,000
purchase of treasury stock															-19,048,000	-254,391,000
financing lease liabilities arising from obtaining financing lease assets															0	0
loss on disposal of property and equipment												19,000			3,000	-3,000															0	0
cash taxes paid
net amortization of premium (accretion of discount) on marketable securities										-2,776,000		-661,000	232,000	1,150,000	1,623,000	1,904,000	1,758,000	1,664,000
deferred revenue														2,500,000																																	-6,268,000	-6,268,000
net cash from financing activities - discontinued operations
adjustments to reconcile net income from continuing operations to net cash from operating activities:
net cash from financing activities - continuing operations												1,187,000	-67,000	1,208,000		-250,985,000	-503,458,000	7,261,000
proceeds from public offering of common stock, net of reimbursements
operating lease liabilities arising from obtaining operating lease assets																							0	-534,000
non-cash interest expense associated with the sale of future revenue																			6,014,000	9,767,000
non-cash royalty revenue																			-2,953,000	-2,691,000
collaboration receivable – related party																			211,000	203,000	40,000	-1,038,000	299,000	686,000	-205,000	143,000	933,000	15,931,000	-15,814,000	-1,064,000	1,041,000	1,353,000	6,423,000	-6,379,000	3,296,000	-329,000	-1,039,000	1,411,000	852,000	1,397,000	-3,458,000	-524,000	12,267,000
collaboration receivable – other																			44,000	-165,000	206,000	-105,000	-1,059,000	1,353,000	-582,000	-970,000	-230,000	0
royalty receivable – related party																			0	1,650,000	1,650,000	-400,000	-300,000	100,000	-500,000	34,000	-371,000	-290,000	-156,000	-195,000	-507,000
deferred revenue – related party																			0	0	-4,748,000	-56,765,000	-5,157,000	-3,400,000	-7,058,000	-15,391,000	-15,916,000	-5,105,000	-7,503,000	-3,141,000	-6,429,000	-8,957,000	-9,260,000	-1,924,000	-20,146,000	-4,653,000	196,537,000	-5,892,000	-4,525,000	-3,108,000	24,979,000	-31,393,000	-6,789,000	-15,141,000
deferred rent																											-138,000	72,000	-112,000	96,000	-210,000	-866,000	-852,000	-801,000	-820,000	1,353,000	1,373,000	-560,000	256,000	1,860,000	5,471,000	8,218,000	3,611,000	135,000	-31,000	-24,000
reimbursement (payment) of public offering costs
proceeds from the sale of future revenue, net of issuance costs																			0	0
proceeds from stock option exercises in other current assets																									-1,037,000	1,149,000	-32,000			73,000				6,000			6,000	17,000	-14,000	197,000	-57,000	60,000	-164,000
net accretion of premium and discounts on investments																				1,048,000	347,000	126,000		-753,000
depreciation																					2,432,000	2,474,000		2,082,000	2,037,000	2,005,000	1,911,000	1,797,000	1,739,000	1,725,000	1,654,000	1,614,000	1,573,000	1,591,000	1,722,000	1,436,000	1,304,000	1,246,000	1,145,000	1,047,000	780,000	370,000	362,000	346,000	327,000	332,000	340,000	377,000
payment of public offering costs, net of reimbursements																												0	-203,000	-188,000
proceeds from public offering of common stock, net of commissions																												0	0	516,206,000	0	0			0
net amortization of premium and discounts on investments																										-1,131,000		-1,249,000	-885,000	-406,000		-69,000	-69,000	163,000		204,000	204,000	126,000				172,000
public offering costs in other current assets, net of amounts in accounts payable and accrued expenses																																			106,000
(payment) reimbursement of public offering costs
public offering costs in other receivables, net of amounts in accounts payable and accrued expenses																																193,000
tenant improvement and other receivables																															372,000	-80,000	2,662,000	-24,000	4,000	-1,089,000	-1,443,000	2,803,000
public offering costs in other current assets																																		329,000
public offering costs in accounts payable and accrued expenses																														158,000
refundable income taxes and income taxes payable																																							0	0	0	3,841,000	0	0	655,000	-5,958,000
net proceeds from stock option exercises and employee stock purchase plan, and vesting of restricted stock units
vesting of restricted stock																																							12,000	-2,000	-6,000	2,000	16,000	-1,000	-9,000	3,000
proceeds from stock option exercises in other receivables																																92,000
adjustments to reconcile net income cash from operating activities:
reimbursement of public offering costs, net of payments
loss on disposal of fixed assets																																		40,000
accrued expenses and other liabilities																																		-6,889,000		8,161,000	2,069,000	-2,902,000	-836,000	5,027,000	-4,132,000	1,574,000	1,817,000	4,544,000	1,064,000	-2,194,000	2,398,000	635,000
payment of public offering costs																																		-100,000	-106,000							-207,000
net income on disposal of fixed assets
net amortization of premiums and discounts on marketable securities
release of restricted cash																																											0
net proceeds from stock option exercises and employee stock purchase plan and vesting of restricted stock units
net increase in cash and cash equivalents																																			-124,748,000	51,454,000	195,013,000	-32,729,000	-8,284,000	7,515,000	37,277,000	21,225,000		-38,198,000			-34,451,000
supplemental cash flow information
cash paid for income taxes																																											22,000	0	0	5,958,000
additions to property, plant and equipment included in accounts payable and accrued expenses
additions to property, plant and equipment in accounts payable and accrued expenses																																				-863,000	753,000	607,000				6,602,000
prepaid expenses and other assets																																					-272,000	-857,000	-1,451,000	-2,442,000	833,000	-708,000	-122,000	-1,965,000	139,000	-930,000	122,000	1,006,000
deferred taxes
net amortization of premiums and discounts on investments
proceeds from private placement
net proceeds from stock option exercises and issuance of common stock																																												380,000	454,000	582,000
conversion of convertible preferred stock upon initial public offering
net amortization of premium on investments																																								112,000
net proceeds from public offering of common stock, (payment of) commissions and offering costs																																								0
net proceeds from stock option exercises and issuance of common and restricted common stock
net decrease in cash and cash equivalents																																														-38,723,000
proceeds from public offering of common stock, net of commissions and offering costs																																												-13,000
additions to property, plant and equipment included in accounts payable																																												185,000	-1,000	13,000
conversion of convertible preferred stock into common stock
public offering costs included in accounts payable
net amortization (accretion) of premium (discount) on investments																																													137,000	168,000
unbilled collaboration receivable – related party
unbilled collaboration receivable—related party																																														-2,143,000
deferred revenue—related party																																														-6,268,000
accrual of public offering costs																																														65,000
unbilled collaboration receivable
proceeds from initial public offering, net of commissions
payment of initial public offering costs
net proceeds from issuance of series c convertible preferred stock
amortization (accretion) of premium (discount) on investments
proceeds from initial public offering and private placement of common stock
net proceeds from stock option exercises
non-cash financing activities
initial public offering costs incurred but unpaid at period end
amortization of (discount) premium on investments

We provide you with 20 years of cash flow statements for Agios Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Agios Pharmaceuticals stock. Explore the full financial landscape of Agios Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Agios Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.